A Phase 4 interventional study of Intracervical injection of Vasopressin and Intracervical Injection of saline in Retained Products of Conception, sponsored by Prisma Health-Upstate. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 51 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Prisma Health-Upstate · Phase 4, Interventional, and Treatment
This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus.
The main goal of the study is :
Participants will:
This double-blinded randomized control trial is designed to evaluate if intraoperative injection of intracervical vasopressin into the cervix will allow for completion of hysteroscopic removal of retained products of conception. This will be measured by surgical completion comparing patients who received intracervical vasopressin and those receiving placebo. Surgical completion is defined by completing the procedure without having to convert to suction of tissue due to bleeding or poor visualization. Secondary outcome measures include intraoperative bleeding, operative time, fluid deficit, and deficit volume.
Prisma Health-Upstate is the lead sponsor of 76 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vasopressin- 20 mL of a dilute solution (5 units of Vasopressin in 20cc injectable saline)
Drug: Intracervical injection of Vasopressin
20 mL of saline
Drug: Intracervical Injection of saline
Intracervical injection of Vasopressin
Intracervical Injection of saline
Completion of procedure hysteroscopically
There is complete removal of RPOC hysteroscopically by the end of the procedure.
Time frame: from start of procedure to end of procedure
Intraoperative Bleeding
calculated by dividing the number of red blood cells per milliliter of outflow distention fluid by the number of red blood cells per milliliter of the woman's blood immediately before the procedure and multiplying this quotient by the total amount of outflow fluid collected
Time frame: from start of procedure to end of procedure
Operative time
time from insertion of hysteroscope to procedure completion
Time frame: time from insertion of hysteroscope to procedure completion
fluid deficit volume
The difference between the total volume of distension fluid infusion into the uterine cavity during the hysteroscopy and the volume of fluid recovered from the outflow.
Time frame: from start of procedure to end of procedure
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prisma Health-Upstate